NPM1 and acute myeloid leukemia: In conclusion, checkpoint blockade offers a novel therapeutic avenue in NPM1-mutated AML, but further clinical trials are essential for optimizing treatment protocols, identifying predictive biomarkers and establishing long-term benefits for patients.